0:00

What about tomosynthesis guided biopsy of calcification? So, um, you know, I've,

0:05

we talked about stereotactic guidance before using that plus and minus 15 degree

0:09

images to localize the, the finding. And, um, although, you know,

0:13

I've only talked about biopsying like distortions and asymmetries, um,

0:17

really that was primarily, that's been primarily used to biopsy calcifications.

0:21

Uh, but in our,

0:23

once we started doing using three d biopsy for these other findings,

0:27

we also started using it for ba calcifications. And anecdotally, we,

0:30

I think people in our group really enjoyed using it. They felt like it was,

0:33

it was quicker. We took fewer images. There had been, um,

0:36

some studies on the use of it, but there hadn't been very many.

0:40

So we decided to, to look at our own experience with, uh,

0:43

tomosynthesis guided biopsy of calcification. So this was a, a paper published,

0:47

um, pretty recently this past year, um,

0:51

in a j r where we looked, we compared our, um,

0:54

diagnostic mammography guided biopsy or,

0:57

or the traditional stereotactic biopsy with tomosynthesis guided biopsy for

1:01

suspicious breast calcifications. Uh, we included, uh,

1:06

over 1300 biopsies in their research study.

1:10

And we found that we,

1:11

we performed almost three quarters of our biopsies using tomosynthesis guidance

1:16

and only about a quarter with stereotactic only guidance.

1:20

And I think that really speaks to just the, our radiologists were getting,

1:23

were very comfortable using tomosynthesis guidance and,

1:25

and felt like it was working well for them. When we compared these two groups,

1:30

the tomosynthesis guidance group, with the stereotactic Guidance group,

1:33

we found that the procedure time and the number of exposures was significantly

1:37

lower when we used tomosynthesis guidance compared to the stereotactic guidance.

1:42

And it was statistically significant.

1:44

We did not show any difference between biopsy outcomes or high risk lesion

1:48

upgrade rate. You know,

1:50

we wanna make sure that we're still diagnosing as many similar numbers of

1:53

cancers similar, we're not under, um,

1:56

under diagnosing cancers or finding, um,

1:59

that more of our high-risk lesions are being upgraded.

2:01

But we didn't find any differences in those outcome metrics.